person lying on white concrete bench during daytime

Clinical studies of MT-1’s impact on tanning in animals exposed to UV light have been conducted in phase 1. MT-1 was shown to increase tanning by 75% and decrease sunburn risk by 47% in study participants. To attain the same level of tan as in the control group, participants administered Melanotan 1 needed 50% less exposure to UV radiation. They had a darker tan for three weeks longer than those exposed exclusively to UV radiation. Some experts believe that the tanning enhancer Melanotan 1 might be utilized to avoid sunburn and the long-term consequences of ultraviolet skin damage. This might be especially helpful for those with fair skin who cannot get a tan (known as type I and type II by the Fitzpatrick scale).

According to research, those with mutant MC1 receptors are less likely than the standard subject to get a tan. For those who don’t get sunburns quickly, Melanotan 1 for sale has been shown to significantly enhance the density of melanin in the skin, which helps protect them from the sun’s harmful rays. Those at risk for skin cancer must drastically reduce their time in the sun if they want to obtain any benefit from sunscreen at all. The findings of this study might pave the way for improved UV protection and a significant decrease in the incidence of skin cancer.

Melanotan 1 may also be used to treat vitiligo. Melanotan 1 and UVB light treatment enhanced both melanin synthesis and the growth of the melanocytes that create melanin in a modest phase 1 study. Repigmentation and better vitiligo pigmentation were seen in almost half of those treated. Adding Melanotan 1 therapy to current vitiligo treatment methods has created synergistic benefits and better cosmetic results in shorter periods. If Melanotan 1 therapy helps treat vitiligo, it may have other uses, such as treating hypopigmented scars.

Acne, also known as actinic keratosis, is an unsightly, crusty development on the skin caused by overexposure to ultraviolet radiation. If left untreated, it will progress to squamous cell carcinoma (a kind of skin cancer), considered a precancerous lesion. Every year, there are around 400,000 new cases. Even though dermatologists and surgeons may remove visible lesions, the overwhelming majority are so tiny that they are not detectable by touch. Research on the efficacy of Melanotan 1 in treating and preventing the growth of precancerous skin lesions is now underway.

Melanotan 1 and Blood Pressure Research

It has been shown that Melanotan 1 can safeguard against high blood pressure in hypertensive mice without adversely affecting animals with normal blood pressure. Taking current blood pressure medications might result in hypotension, leading to several health problems, including loss of consciousness, a stroke, a heart attack, and more. It is more frequent among the elderly because of their shaky physiology, which may lead to the adverse effect of blood pressure medications. Melanotan 1’s capacity to control high blood pressure sans triggering major lows makes it an ideal option for future medication development.

Melanotan 1 with Dementia, Alzheimer’s, and Cognitive Decline

According to research, Melanotan 1 protects the brain against the damage that causes cognitive decline and Alzheimer’s disease in transgenic mice. It was found that even at shallow doses, Melanotan 1 reduced amyloid-beta plaque levels in the brain, protected neurons from death, and improved clinical measures of cognitive function as well as laboratory measurements of synaptic transmission in a mouse model of moderate Alzheimer’s disease (AD). The positive effects of the peptide were negated entirely in the same research when Melanotan 1 was blocked at the MC4 receptor.

In previous research, Melanotan 1 has been shown to have a positive effect on the MC4 receptor. MC4 receptor activation has been shown to increase neurogenesis and aid cognitive recovery in Alzheimer’s disease in studies conducted on mice. Few investigations have shown that the disease may improve rather than slow down. Multiple pathophysiological mechanisms are activated by the daily dose of MT-1, which lowers levels of all AD-related biomarkers.